Literature DB >> 2221860

Meropenem pharmacokinetics and penetration into an inflammatory exudate.

R Wise1, M Logan, M Cooper, J P Ashby, J M Andrews.   

Abstract

The pharmacokinetics and penetration into a cantharidine-induced inflammatory exudate of meropenem was studied in six volunteers following a single 1-g intravenous dose. Concentrations in plasma, urine, and the inflammatory exudate were determined by a microbiological assay. The mean elimination half-life of meropenem in plasma was 1.1 h, with the concentration in plasma declining from a mean of 23.6 micrograms/ml at 1 h to 0.7 micrograms/ml at 6 h. The inflammatory fluid penetration was rapid (time to maximum concentration of drug in serum, 0.75 h), and the penetration was 111%. The recovery of meropenem in urine at 24 h was 65.4% of the administered dose.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2221860      PMCID: PMC171864          DOI: 10.1128/AAC.34.8.1515

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Pharmacokinetics and tissue penetration of cefepime.

Authors:  K J Nye; Y G Shi; J M Andrews; R Wise
Journal:  J Antimicrob Chemother       Date:  1989-07       Impact factor: 5.790

2.  Pharmacology of imipenem.

Authors:  M R Lockley; R Wise
Journal:  J Antimicrob Chemother       Date:  1985-10       Impact factor: 5.790

3.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

Review 4.  In vitro and pharmacokinetic properties of the carbapenems.

Authors:  R Wise
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

5.  PHARM--an interactive graphic program for individual and population pharmacokinetic parameter estimation.

Authors:  R Gomeni
Journal:  Comput Biol Med       Date:  1984       Impact factor: 4.589

6.  The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics.

Authors:  R Wise; A P Gillett; B Cadge; S R Durham; S Baker
Journal:  J Infect Dis       Date:  1980-07       Impact factor: 5.226

7.  In-vitro studies of meropenem.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

8.  Disposition of radiolabeled imipenem and cilastatin in normal human volunteers.

Authors:  S R Norrby; J D Rogers; F Ferber; K H Jones; A G Zacchei; L L Weidner; J L Demetriades; D A Gravallese; J Y Hsieh
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

Review 9.  The carbapenems: new broad spectrum beta-lactam antibiotics.

Authors:  R C Moellering; G M Eliopoulos; D E Sentochnik
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

10.  In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I.

Authors:  J R Edwards; P J Turner; C Wannop; E S Withnell; A J Grindey; K Nairn
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

View more
  20 in total

1.  Pharmacokinetic profile of meropenem, administered at 500 milligrams every 8 hours, in plasma and cantharidin-induced skin blister fluid.

Authors:  Dana Maglio; Renli Teng; Per T Thyrum; Charles H Nightingale; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

Review 2.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

3.  Pharmacokinetics of the penem CP-65,207 and its separate stereoisomers in humans.

Authors:  G Foulds; A K Knirsch; J D Lazar; T G Tensfelt; N Gerber
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

4.  Penetration of fleroxacin and ciprofloxacin into skin blister fluid: a comparative study.

Authors:  T J Lubowski; C Nightingale; K Sweeney; R Quintiliani; J Zhi
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

5.  Appropriate antibiotic dosage levels in the treatment of severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Maya Hites; Marjorie Beumier; Sabino Scolletta; Frédérique Jacobs
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

6.  Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin.

Authors:  M Dreetz; J Hamacher; J Eller; K Borner; P Koeppe; T Schaberg; H Lode
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

7.  Measurement of vancomycin hydrochloride concentration in the exudate from wounds receiving negative pressure wound therapy: a pilot study.

Authors:  Yukiko Ida; Hajime Matsumura; Masami Onishi; Sayaka Ono; Ryutaro Imai; Katsueki Watanabe
Journal:  Int Wound J       Date:  2014-03-28       Impact factor: 3.315

Review 8.  Meropenem clinical pharmacokinetics.

Authors:  J W Mouton; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

9.  Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Pierre-François Laterre; Thierry Dugernier; Herbert Spapen; Isabelle Delattre; Xavier Wittebole; Daniel De Backer; Brice Layeux; Pierre Wallemacq; Jean-Louis Vincent; Frédérique Jacobs
Journal:  Crit Care       Date:  2010-07-01       Impact factor: 9.097

Review 10.  Future directions in antimicrobial chemotherapy.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1992-08-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.